| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d411f057afd16fae0abb5bd931e8130c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-723
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-717 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-717
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-723
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 |
| filingDate |
2008-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76d2b8b08dcc6d689da2e4f7c07b2eb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10c8e8d6b921c730f095ea5bb743d414
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9b5f76bcaac4f496c438c9dcdd1718d |
| publicationDate |
2008-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008143914-A |
| titleOfInvention |
Pharmaceutical composition for treating inflammatory bowel disease |
| abstract |
An active ingredient useful for the treatment or prevention of inflammatory bowel disease (IBD), particularly Crohn's disease, left ulcerative colitis or cystitis, a pharmaceutical composition containing the active ingredient, and a dosage form of the pharmaceutical composition Offer. A pharmaceutical composition for rectal administration comprising xanthan gum as an active ingredient for treating or preventing IBD and containing the compound as a single therapeutic active ingredient, and as a dosage form of the pharmaceutical composition Liquid enema or foam enema. The liquid enema contains xanthan gum at a concentration of 0.4-2% w / w (based on the composition). The effervescent enema contains xanthan gum at a concentration of 1.4 to 2.5% w / w (based on the composition). [Selection figure] None |
| priorityDate |
1997-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |